Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Investment Arm of Asia-Based Pharmaceutical Company Seeks Equity Investment and In-Licensing Opportunities in Novel Therapeutic Modalities

26 Jan

A pharmaceutical company headquartered in Asia has 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.). The firm’s main business covers chemical and biological medicines, pharmaceutical packaging, and trading.

The firm’s investment subsidiary is responsible for equity investment and in-licensing activities for its corporate parent.

The firm is most interested in companies developing novel drugs in Biologics, Cell therapy, Gene therapy, Repurposed drugs, and Biosimilars. The firm is interested in distribution rights in China. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Investment Firm Invests Up to $40M in Early Clinical Stage Therapeutics, Medical Devices, and Diagnostics Companies

5 Jan

A global investment firm with bases in USA and Asia is primarily focused on healthcare investments and looks to make allocations ranging from $1M to $40M depending on opportunity and risk/reward. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space the firm is interested in Therapeutics, Medical Devices, and Diagnostics. The firm is currently most interested in companies with some clinical data however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and publicly held companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Venture Capital Firm Invests in Early-Stage Therapeutics, Diagnostics, and Life Science Tools With Strong Intellectual Property

5 Jan

A venture capital firm focuses on early-stage diagnostics, life science research tools, and biotech-related companies. The firm’s target initial investment size is $1-$2M. The firm prefers to act as the co-investor with other types of investors such as strategic partners. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early-stage diagnostics, life science research tools, and biotech-related companies. The firm will invest in a limited number of therapeutic opportunities.  The firm is opportunistic in terms of subsectors and indications. The firm will consider investing in companies that have strong intellectual property protection and provide barriers to competitive entry. The firm also seeks companies with potential large addressable markets, which typically have the potential to generate at least $50M of annual revenues.

The firm backs management teams that listen to the market, develop new products to provide customer value by meeting unmet needs and/or delivering an order of magnitude improvement to the customer. They focus on CEOs that are driven to deliver exceptional investment returns to both investors and management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm of a Large Holding Company Invests in Novel Therapeutics and Medtech Technologies in CNS, Autoimmune Diseases, and More

5 Jan

A corporate venture arm of a holding company seeks to foster innovation across the group by investing in and partnering with strategic startups. In principle, the corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/Medical is one of the major focus areas of the group. The firm is interested in therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. Corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data.  Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm of MCG has a close, collaborative relationship with other branches within the group and can also present opportunities to the pharma branch, CRO, CDMO branches as appropriate.

The firm is a flexible investor. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. The venture group has a close relationship with all other business operations within the holding company and can actively support companies by leveraging these relationships.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm Allocates Up to $20M in Early-Stage Opportunities in Therapeutics and Therapeutic Medical Devices

5 Jan

A venture capital firm with multiple offices in the US manages assets under management of $1.6 billion. Since inception, the firm has raised five investment funds. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity.

The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.

The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Builder and Investor Invests up to $1M Globally in Pre-Seed and Seed Stage Companies

29 Dec

The venture fund and venture builder invests in multiple healthcare sectors including therapeutics and synthetic biology, life science tools, IVD, medical devices, digital health and microbiome. The firm invests in pre-seed/seed stage companies with some proof of concept, looking to be the first institutional money in. The firm will invest globally, and looks to invest between $400k-1M. As an igniter, the firm takes a very active role in company formation, development and executive management.

The firm is interested in therapeutics, life science tools, medical devices, synthetic biology, and microbiome related technologies. Within these areas, anything relevant will be considered, including digital health and in vitro diagnostics. The firm is agnostic to indication.

The firm only invests in the first institutional capital round. The firm can invest, or act as a co-founder, depending on the needs of the company/founding team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: California Based Venture Fund Investing $1-15M in Precision Medicine, Medical Devices and AI-Enabled Services

29 Dec

The investor is a Venture Capital firm based in San Francisco California. The firm is interested in making equity investments into early stage companies with investments ranging from $1M to $15 million per company, depending on the companies needs and stage of development. The firm is currently seeking investment opportunities throughout the United States.

The firm is looking for companies operating in Precision medicine, MedTech and medicine at the edge, AI-enabled services such as drug discovery and clinical trial support, and synthetic biology with a software component. The firm is entirely opportunistic in terms of indication and will consider companies at all stages of development.

The firm is looking for privately held companies with strong management teams. The firm is able to provide entrepreneurs with a 200-person advisory network and bring deep operational expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: